Clinical Trials Logo

Filter by:
NCT ID: NCT06469450 Recruiting - Pharmacodynamics Clinical Trials

KF2023#1-Trial: Influence of Statin Intake on Cellular Readouts

Start date: April 20, 2024
Phase: Phase 1
Study type: Interventional

A majority of high-risk patients does not achieve their cholesterol target levels and most of these patients do not receive more effective combination therapy, which goes beyond statin monotherapy. Large interindividual differences in treatment outcomes have been observed for patients receiving statins. Statins block cholesterol synthesis and increase cellular low-density lipoprotein (LDL) uptake. Importantly, LDL uptake is highly divergent in individuals.The aim of this trial is to investigate how atorvastatin influences leukocyte readouts of LDL uptake and lipid storage in humans. The trial is a single-arm, open-label, interventional trial. A total of 15 healthy volunteers will receive 40 mg atorvastatin once a day for 4 weeks. The participants will provide blood samples before starting the atorvastatin intervention, each week when taking atorvastatin, and one week after the end of the intervention for the measurement of leukocyte readouts of LDL uptake and lipid storage.

NCT ID: NCT06464003 Recruiting - Malocclusion Clinical Trials

Orthodontic Screening in Public Healthcare

Start date: June 6, 2024
Phase:
Study type: Observational

The aim of the study is to examine orthodontic screening practises in public health care.

NCT ID: NCT06460077 Enrolling by invitation - Multiple Sclerosis Clinical Trials

Exploring Pathology Related to Slowly Expanding Lesions Using Advanced Imaging

SELPET
Start date: June 2024
Phase:
Study type: Observational

This is an open, follow-up study to compare the performance of three critical imaging methods to detect chronic active lesions in MS in vivo.

NCT ID: NCT06453538 Recruiting - Clinical trials for Coronary Artery Disease

Sleep Quality and Sleep-disordered Breathing in Bypass Surgery Patients

UNI-CABG
Start date: February 1, 2023
Phase:
Study type: Observational

To this study is recruiting non- emergency patients to whom are planning to make coronary artery bypass intervention. From all patients are going to examine transthoracic echo, collect blood samples and register overnight sleep polygraph in a qualified sleep laboratory two times; first before cabg and second one after surgery.

NCT ID: NCT06452277 Not yet recruiting - Clinical trials for Advanced Non-small Cell Lung Cancer

A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)

SOHO-02
Start date: June 24, 2024
Phase: Phase 3
Study type: Interventional

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building plans (genes) for this protein in cancer cells leads to a production of abnormal HER2 and therefore abnormal cell growth and division. The study treatment, BAY 2927088, is expected to block the mutated HER2 protein which may stop the spread of NSCLC. The main purpose of this study is to learn how well BAY 2927088 works and how safe it is compared with standard treatment, in participants who have advanced NSCLC with specific genetic changes called HER2 mutations. The study participants will receive one of the study treatments: - BAY 2927088 twice every day as a tablet by mouth, or - Standard treatment in cycles of 21 days via infusion ("drip") into the vein. The treatment will continue for as long as participants benefit from it without any severe side effects or until they or their doctor decide to stop the treatment. During the study, the doctors and their study team will: - take imaging scans, including CT, PET, MRI, and X-rays, of different parts of the body to study the spread of cancer - check the overall health of the participants by performing tests such as blood and urine tests, and checking - heart health using an electrocardiogram (ECG) - perform pregnancy tests for women - ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.

NCT ID: NCT06451744 Recruiting - Lichen Planus Clinical Trials

Cellular and Molecular Biomarkers in Patients With Lichen Planus

HELP
Start date: November 1, 2023
Phase: N/A
Study type: Interventional

Lichen planus (LP) is a chronic inflammatory disease of unknown aetiology, affecting the skin and mucous membranes, characterised by a CD8+ cytotoxic T-cell infiltrate, associated with epithelial cell death and disruption of the basement membrane zone. In previous work, T cell antigen receptor (TCR) repertoire studies were performed. In all patients tested, whether with erosive or non-erosive LP, unique nucleotide sequences, called clonotypes, have been identified. They appear during the process of TCR gene rearrangement. These clonotypes are specific for human papillomavirus (HPV) in blood and lesions, suggesting antigenic stimulation of these clonotypes by a viral epitope of HPV, which crosses with an epitope on keratinocytes. The diagnosis of LP is made on the basis of clinical and histological criteria, but in some patients and in some anatomical locations, the diagnosis is difficult to make and LP may be confused with other skin conditions.

NCT ID: NCT06448117 Not yet recruiting - Quality of Life Clinical Trials

Mind Nutrition Study: Nutrition in the Prevention of Depressiveness and Sustaining Work Ability

Start date: September 1, 2024
Phase: N/A
Study type: Interventional

The goal of this randomized, controlled trial is to examine the effectiveness of dietary counseling on the risk of depressiveness, work ability, and quality of life in mental health professionals. The main questions it aims to answer are: - Whether dietary counseling can lower the risk of depression and depression-related sick leave days and improve work ability among mental health professionals - Whether dietary counseling can improve life quality, diet quality, and eating behavior among mental health professionals. Subjects of the intervention group will participate in five dietary counseling sessions during six months. Participants in the control group do not receive any intervention. Researchers will compare the intervention and control groups to see if dietary counseling is effective in reducing the risk of depressiveness and depression-related sick leave days and improving work ability, quality of life, and nutritional habits.

NCT ID: NCT06438276 Recruiting - Depression Clinical Trials

Psychiatric Outreach Nurses Supporting Adolescent Mental Health

JAPSY
Start date: May 6, 2024
Phase:
Study type: Observational

The study evaluates the effectiveness and cost-effectiveness of the outreach work of psychiatric registered nurses (RN) and the experiences of professionals in the field. The service is provided in school environment. First, the study will assess the effectiveness of brief interventions provided by psychiatric outreach nurses on the perceived mental health and quality of life of adolescents (12-16 year old pupils) and their use of social and health services, compared to the support/treatment provided by conventional student welfare services at 6 and 12 months follow-up. The intervention is an outreach service provided by psychiatric nurses. In the intervention, the psychiatric registered nurse will implement interventions such as usual care, discussion, psychoeducation, substance abuse skills and various methods (such as interpersonal psychotherapy = IPT-N and Cool Kids) and motivational interviewing. Secondly, an economic evaluation of the service will be carried out at 6 and 12 months follow-up. The economic evaluation will be carried out from the perspective of the Wellbeing Services County, including the costs of implementing the intervention model and its effects on adolescents' use of student welfare services as well as other social and health services. Primarily, the economic evaluation will use quality-weighted life years as a measure of effectiveness. Also analysis using depression, anxiety and substance use measures will be conducted. Thirdly, the study will explore the experiences of psychiatric nurses implementing the service as well as the experiences of their collaborators in schools (public health nurses, school social workers, psychologists, doctors and teachers) about the service and its implementation.

NCT ID: NCT06431594 Not yet recruiting - Solid Tumors Clinical Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Start date: June 21, 2024
Phase: Phase 1
Study type: Interventional

The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount.

NCT ID: NCT06418321 Recruiting - Clinical trials for Hearing Loss, Age-Related

Early Identification of Age-related Hearing Impairment

Start date: April 4, 2024
Phase:
Study type: Observational

The need for future hearing rehabilitation is enormous. World Health Organization (WHO 2021) has estimated that by 2050, 2.5 billion people will have some degree of hearing loss, and 1/4 of them will require hearing rehabilitation. Currently, healthcare systems and processes are already overwhelmed and not adequately equipped to screen and diagnose this rapidly growing population suffering from hearing impairment. This study aims to investigate if the diagnostics of age-related hearing loss can be accelerated by involving patients in the hearing assessment process.